FORMOSA PHARMACEUTICALS , INC
Area: Pharmaceutical and Medical Devices
Booth No: M306
Website: https://www.formosapharma.com
Exhibitor Profile
Formosa Pharmaceuticals, founded in 2010, is a clinical stage biotechnology company with assets in ophthalmology, oncology.
Seeking out-licensing or co-development opportunities :
* APP13007 (Ophthalmic Nanosuspension for Inflammation and Pain after Ocular Surgery) [US FDA approved]
* TSY-0110 (ADC biosimilar of Kadcyla (T-DM1)) [Late-preclinical stage]
* APNT Nanoparticle Formulation Platform
* Co-development or strategic in-license ADC novel agents and ophthamology assets
Brands
FORMOSA PHARMACEUTICALS , INC
Video
Exhibit Products
-
APP13007 - Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery
-
APP13002 - Infectious Eye Diseases Treatment
-
TSY-0110 - Kadcyla (T-DM1) Biosimilar
-
APNT Nanoparticle Formulation Platform
Exhibitor Press Release
- Formosa Pharmaceuticals Announces Licensing Agreement With Eyenovia for APP13007 Commercialization 2024-03-28
- Formosa Pharmaceuticals Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05% 2024-03-28
- Formosa Pharmaceuticals Announces Licensing Agreement With Cristália for APP13007 2024-03-28
Exhibitors you may be interested in
Highest Rated